A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK) DOI Creative Commons
C. Mary Schooling, Guoyi Yang, Ghada A. Soliman

и другие.

Life, Год журнала: 2025, Номер 15(2), С. 253 - 253

Опубликована: Фев. 7, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce bodyweight and blood glucose. Extensive evidence from randomized controlled trials has indicated that GLP-1RAs have benefits well beyond weight loss glucose control, extending reductions in cardiovascular mortality to prostate cancer risk. Notably, some of for the cardiovascular–kidney–metabolic (CKM) system arise before occurs reasons are not entirely clear but key patient care drug development. Here, we hypothesize act by inducing calorie restriction activating adenosine monophosphate-activated protein kinase (AMPK), which only provides an explanation unique effectiveness also indicates a common mechanism shared effective CKM therapies, including salicylates, metformin, statins, healthy diet, physical activity. Whether AMPK activation is obligatory therapies should be considered. As such, propose action explain how it overarching framework identifying means preventing treating cardiovascular, kidney, metabolic related diseases, as informing complementary question components lifestyle.

Язык: Английский

A Hypothesis That Glucagon-like Peptide-1 Receptor Agonists Exert Immediate and Multifaceted Effects by Activating Adenosine Monophosphate-Activate Protein Kinase (AMPK) DOI Creative Commons
C. Mary Schooling, Guoyi Yang, Ghada A. Soliman

и другие.

Life, Год журнала: 2025, Номер 15(2), С. 253 - 253

Опубликована: Фев. 7, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce bodyweight and blood glucose. Extensive evidence from randomized controlled trials has indicated that GLP-1RAs have benefits well beyond weight loss glucose control, extending reductions in cardiovascular mortality to prostate cancer risk. Notably, some of for the cardiovascular–kidney–metabolic (CKM) system arise before occurs reasons are not entirely clear but key patient care drug development. Here, we hypothesize act by inducing calorie restriction activating adenosine monophosphate-activated protein kinase (AMPK), which only provides an explanation unique effectiveness also indicates a common mechanism shared effective CKM therapies, including salicylates, metformin, statins, healthy diet, physical activity. Whether AMPK activation is obligatory therapies should be considered. As such, propose action explain how it overarching framework identifying means preventing treating cardiovascular, kidney, metabolic related diseases, as informing complementary question components lifestyle.

Язык: Английский

Процитировано

1